Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats

Journal of Hypertension

Volumn 22, Issue 5, 2004, Pages 1007-1015

  Kagitani, Satoshi ^a   Ueno, Hitoshi ^a   Hirade, Satoshi ^a   Takahashi, Toru ^a   Takata, Masanobu ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Deoxycorticosterone acetate salt hypertensive rats; Monocyte macrophage; Myocardial fibrosis; Tranilast; Transforming growth factor 1

Indexed keywords

ANTIINFLAMMATORY AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM CHLORIDE; PROCOLLAGEN; SODIUM CHLORIDE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; FIBROSING ALVEOLITIS; HEART MUSCLE FIBROSIS; HYPERTENSION; INFLAMMATORY CELL; MACROPHAGE; MALE; MONOCYTE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS;

EID: 2542466164     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200405000-00024     Document Type: Article

References (31)

1. Weber KT, Sun Y, Guarda E. Nonclassic actions of angiotensin II and aldosterone in nonclassic target tissue (The heart): Relevance of hypertensive heart disease. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995, pp. 2203-2223.
2. Fujisawa G, Dilley R, Fullerton MJ, Funder JW. Experimental cardiac fibrosis: Differential time course of response to mineralocorticoid-salt administration. Endocrinology 2001; 142:3625-3631.
3. Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol 1998; 30:475-483.
4. Hilgers KF, Hartner A, Porst M, Mai M, Wittmann M, Hugo C, et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int 2000; 58:2408-2419.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
6. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension 2002; 39:679-684.
7. Suzawa H, Kikuchi S, Ichikawa K, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 1992; 60:85-90.
8. Wilmer WA, Tan LC, Dickerson A, Danne M, Rovin BH. Interleukin-1β induction of mitogen-activated protein kinase in human mesangial cells. J Biol Chem 1997; 272:10877-10881.
9. Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Kossamehl P, Hocher B, et al. Reduction in left ventricular messenger RNA for transforming growth factor beta (1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 Rat. Hypertension 2000; 36:747-754.
10. Hocher B, Godes M, Olivier J, Weil J, Eschenhagen T, Slowinski T, et al. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens 2002; 20:745-751.
11. Chikaraishi A, Hirahashi J, Takase O, Marumo T, Hishikawa T, Hayashi M, et al. Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. Eur J Phamacol 2001; 427:151-158.
12. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999; 10:S143-S148.
13. Ueno H, Kanellakis P, Agrotis A, Bobik A. Blood flow regulates the development of vascular hypertrophy, smooth muscle cell proliferation, and endothelial cell nitric oxide synthase in hypertension. Hypertension 2000; 36:89-96.
14. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61:1684-1695.
15. Kobayashi N, Mori Y, Nakano S, Tsubokou Y, Shirataki H, Matsuoka H. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001; 19:795-801.
16. Ward MR, Sasahara T, Agrotis A, Diley RJ, Jennings GL, Bobik A. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis 1998; 137:267-275.
17. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987; 262: 17467-17474.
18. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106:130-135.
19. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: Effect of endothelin ETA receptor antagonism. Circulation 2001; 103:319-324.
20. Hara K, Kobayashi N, Watanabe S, Tsubokou Y, Matsuoka H. Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 2001; 14:321-330.
21. 1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 2000; 35:86-90.
22. Kovacs EJ. Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 1991; 12:17-23.
23. Miyazawa K, Fukuyama J, Misawa K, Hamano S, Ujiie A. Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Atherosclerosis 1996; 121:167-173.
24. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98:149-156.
25. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariety J, et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 1994; 70:286-294.
26. Agelli M, Wahl SM. Cytokines and fibrosis. Clin Exp Rheumatol 1986; 4:379-388.
27. Nicoletti A, Michel J-B. Cardiac fibrosis and inflammation: Interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41:532-543.
28. Tomita H, Egashira K, Kubo-Inoue M, Usui M, Koyanagi M, Shimokawa H, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol 1998; 18:1456-1464.
29. Jin D, Takai S, Shiota N, Miyazaki M. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur J Pharmacol 1998; 361:199-205.
30. Asano N, Ogura T, Mimura Y, Makino H. Renal AT1 receptor: computerized quantification in spontaneously hypertensive rats and DOCA-salt rats. Res Commun Mol Pathol Pharmacol 1998; 100:171-180.
31. Fareh J, Touyz RM, Schiffrin EL, Thibaut G. Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats. Hypertension 1997; 30:1253-1259.